瑞科生物 REC610 新药上市申请获受理

AASTOCKS
2025.12.29 16:47

RECBIO-B (02179.HK) announced that the new drug application for its adjuvanted recombinant herpes zoster vaccine REC610 has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. Currently, the only adjuvanted recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix

来源：AASTOCKS 本文版权归属原作者/机构所有。
当前内容仅代表作者观点，与本平台立场无关。内容仅供投资者参考，亦不构成任何投资建议。如对本平台提供的内容服务有任何疑问或建议，请联系我们。